XPENG-MOTORS
20.5.2020 01:19:51 CEST | Business Wire | Press release
Xpeng Motors, a leading electric vehicle and technology company, today announced that it has received the official production license from China’s Ministry of Industry and Information Technology for its new own-built, wholly-owned factory, the Zhaoqing Xpeng Motors Intelligent Industrial Park in Guangdong Province.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005994/en/
The approval will accelerate the production of the super-long range sports sedan Xpeng P7, the company’s second production model, ensuring customer deliveries scheduled for 2Q 2020.
“The Zhaoqing manufacturing plant is an essential component of our vision to build a smart mobility ecosystem, from in-house R&D to smart manufacturing to customer services. Obtaining the production approval for the plant will hasten our progress in producing and delivering best-in-class products and services for our customers,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.
“Our success in completing the Zhaoqing plant and rolling out our new P7 smart sedan despite the COVID-19 related challenges is further validation of the strength and robustness of our organization,” He said. The company has secured a sufficient stock of essential parts to ensure smooth manufacturing despite the disruption caused by the COVID-19 pandemic.
Located in Guangdong Province, the home-base of Xpeng Motors, the new Zhaoqing plant has a planned total area of 3,000 acres (2 million square meters), with vehicle production facilities covering some 1,500 acres (1 million square meters). Around 900 acres (600,000 square meters) of it has already been completed in the first phase.
After the foundation-laying in December 2017, the factory construction was completed in September 2019. Since then rigorous pre-production testing and small-scale trial production runs have verified the entire manufacturing process.
The Zhaoqing plant contains five workshops to cover the essential smart manufacturing functions, including stamping, welding, painting, assembly and battery pack production, as well as one battery assembly line, and is capable of manufacturing four different models. Serviced by 264 intelligent industrial robots, the Zhaoqing plant also incorporates dynamic test tracks covering 18 different types of test roads, and testing facilities for NVH, braking, vehicle seals and automatic parking systems.
The Zhaoqing plant is built in accordance with Industry 4.0 standards, with advanced MES manufacturing execution systems, Internet-of-Things technology, real-time production monitoring systems and a transparent manufacturing cycle, delivering the promise of a digital smart factory.
Xpeng has accumulated extensive experience through the production of the G3 smart SUV at the Zhengzhou plant, a partnership with Haima Automobile. By bringing manufacturing in-house, Xpeng is enhancing the autonomy, robustness, flexibility, cost-efficiency and intelligence of its vehicle production.
“The combination of end-to-end closed-loop R&D, smart manufacturing and quality customer services is our key differentiator. Today marks another milestone in Xpeng’s 6-year history, setting a solid foundation in pursuing our vision as a leader in the intelligent EV market,” Chairman He concluded.
For videos and images please visit:
https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook
Twitter
LinkedIn
YouTube
Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005994/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom